Clinical trial
Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
NCT00230334 is registered in ClinicalTrials.gov with Steven E. Coutre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- Lead sponsor
- Steven E. Coutre
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 12, 2003
- Completion date
- May 31, 2007
- Enrollment
- 5 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.